Latest / CME Outfitters Medical Education / Addressing Unmet Needs in Retinal Disease: Pairing Therapeutic Advances with Personalized Care
Transcript
- 0:01SPEAKER_02: Hello, I'm Darius Moshfage, and I'm pleased to welcome you to addressing unmet needs in retinal disease, pairing therapeutic advances with personalized care.
- 0:11SPEAKER_02: This activity is supported through an independent educational grant from Merck Company, Incorporated.
- 0:18SPEAKER_02: During our program today, we may include discussions of products or devices not currently labeled for use by the FDA.
- 0:26SPEAKER_02: We will disclose to you whenever investigational or off-label uses of products or devices are mentioned.
- 0:33SPEAKER_02: Again, I'm Darius Moshvage.
- 0:35SPEAKER_02: I'm Chief of Retina at Stanford University, and I'm pleased to be joined today by Dr.
- 0:39SPEAKER_02: Joseph Coney, who I'll ask to introduce himself.
- 0:42SPEAKER_02: Joe?
- 0:44SPEAKER_01: Well, Darius, thanks for having me today.
- 0:46SPEAKER_01: My name is uh Joe Coney.
- 0:48SPEAKER_01: I am a managing partner at Retina Socialist in Cleveland, Ohio, and I'm glad to be here with you today.
- 0:54SPEAKER_02: Thank you, Joe.
- 0:55SPEAKER_02: And importantly, we have a few short, pre-taped perspectives from a patient who lives with a retinal disease.
- 1:01SPEAKER_02: And as we all know, the patient is central to a successful care team.
- 1:06SPEAKER_02: Here are our learning objectives.
- 1:08SPEAKER_02: After participating in this activity, clinicians should be able to better evaluate guideline recommended strategies for the diagnosis and management of retinal disease, develop individualized management plans for retinal disease that address patient needs and access barriers, and identify the mechanistic link between blood retinal barrier dysfunction and the rationale for emerging therapies for retinal diseases.
- 1:33SPEAKER_02: So perhaps there's no better way to start our program than with a patient who has lived with visual impairment her entire life.
- 1:39SPEAKER_02: And while she does not have the type of retinal disease under discussion today, she has achromatopsia.
- 1:45SPEAKER_02: She offers universal perspectives on living with a retinal disease that impacts daily living.
- 1:50SPEAKER_02: So let's roll the first short video and meet Natasha.
- 1:55SPEAKER_00: Well, my name is Natasha, and I was born with a chromatopsia, but uh my story is a little unique because I was actually adopted from Ukraine when I was two and a half.
- 2:05SPEAKER_00: So my parents adopted me and they like right away, they were like, okay, something's up with her eyes, but they didn't actually know what was wrong.
- 2:13SPEAKER_00: And of course, it's you know, this rare um eye disorder.
- 2:17SPEAKER_00: And um in in middle school, we moved to Tennessee.
- 2:20SPEAKER_00: Luckily, we ended up moving um pretty close to an ophthalmologist who actually specializes in a chromatopsia.
- 2:26SPEAKER_00: Um, and we were able to get the formal diagnosis.
- 2:29SPEAKER_00: Um, I think really my whole life, I was kind of aware that my vision was different.
- 2:34SPEAKER_00: I think the biggest issue for me was in school, it was really prevalent of like not being able to see the board and not being able to see colors and art class.
- 2:42SPEAKER_00: And as I got older, you know, moving into high school, I remember, you know, all my friends turned 16 and they got their license and they could drive.
- 2:48SPEAKER_00: And I still can't drive.
- 2:50SPEAKER_00: I can't see well enough to get a license.
- 2:52SPEAKER_00: Um, and I think the biggest thing for me was when I moved away to college in 2016, um, moved to an entirely new state that I'd never been to before.
- 3:02SPEAKER_00: Um, and that was like really the first time in my life that I really had to advocate for myself and my needs, um, which was definitely a big learning process of like, how do I get groceries?
- 3:11SPEAKER_00: And, you know, how do I talk to my professors about what I need in their classes?
- 3:16SPEAKER_00: Um, and so there were a lot of challenges.
- 3:19SPEAKER_00: Um, yeah, a lot of challenges in in all aspects of my life.
- 3:24SPEAKER_02: Well, that was great hearing from Natasha.
- 3:26SPEAKER_02: Joe, this really resonates with me as a pediatric retina specialist.
- 3:31SPEAKER_02: I'm sure you've seen a lot of this in your own practice.
- 3:34SPEAKER_01: Yeah, you you know, dear, these is these are some of the more frustrating patients that I see in my office because a lot of times there's not a ton of things that I can do.
- 3:43SPEAKER_01: I know when I deal with people that's come in for an evaluation for inherited diseases such as this one, oftentimes these are difficult because their exams sometimes can look normal.
- 3:53SPEAKER_01: And it may take them, you know, several times before they see the physician before you start to do a little deeper dive into their eyes.
- 3:59SPEAKER_01: And as they get older, you may see some clinical changes, but those things are very difficult.
- 4:04SPEAKER_01: But the things that she's gone through and heard at her adaptation, I think, is a story that you and I are so familiar with, particularly when you look at diseases like macular deterioration and diabetes.
- 4:14SPEAKER_01: As people get older, they really learn how to adapt to things.
- 4:18SPEAKER_01: I am always surprised on how people have such visual disabilities, and yet they are living by themselves, they're functioning, they may not be driving.
- 4:28SPEAKER_01: Sometimes they color-code things around our homes, they and they've really got used to using technology.
- 4:33SPEAKER_01: They've learned how to make the screens brighter with contrast or actually or things bigger.
- 4:38SPEAKER_01: So people have adapted, and it's really great to hear that at least she is still able to move on and go to college and still have a normal life.
- 4:46SPEAKER_02: I absolutely agree.
- 4:47SPEAKER_02: And that's a perfect transition, which leads us right into our first learning objective now shown on your screen.
- 4:53SPEAKER_02: Could you kindly set the stage here?
- 4:56SPEAKER_01: So, this little objective is to evaluate the guideline and recommended strategies for diagnosis and management of retinal diseases.
- 5:02SPEAKER_01: And I think this is a big issue for not just what we see in the community, but also things that we see in our office, particularly when it comes to macular degeneration.
- 5:11SPEAKER_01: Uh, this is the leading cause of severe uh impairment in older individuals.
- 5:16SPEAKER_01: Because people are getting older, these things are more common.
- 5:19SPEAKER_01: And we're we're really in a pandemic right now, not just here in the US, but also worldwide, that the number of individuals with diabetes continue to increase.
- 5:27SPEAKER_01: And this is the leading cause of preventable blindness if it's called early.
- 5:31SPEAKER_01: Inherited diseases is a little bit different.
- 5:33SPEAKER_01: These are much rarer genetic retinal degenerations, which causes a progressive loss of vision over time.
- 5:40SPEAKER_01: When it comes to screening, for individuals that have uh macular degeneration, my most concern are those individuals that have a first-degree relative or so in their family that have gone blind.
- 5:51SPEAKER_01: I want to see these individuals around 55 or 65 years of age, depending on their symptoms.
- 5:56SPEAKER_01: If they come in and they don't have any AMD, then I'm okay seeing them every one or two years.
- 6:01SPEAKER_01: The majority of these people are already seeing optometrists, so I can see them intermittently in between those appointments.
- 6:08SPEAKER_01: If they have high risk disease, I'd like to see them a little more often.
- 6:11SPEAKER_01: I think baseline exam is always critical.
- 6:14SPEAKER_01: You should always do a dilated fundoscopic examination.
- 6:17SPEAKER_01: But you know, we see a lot of patients, and so photography for me is really helpful because it helps me to follow those patients long term.
- 6:24SPEAKER_01: I typically do get a fundus photograph, but lately I've really been getting OCTs, even if there's not pathology.
- 6:30SPEAKER_01: But if I think that someone may have a very uh very subtle subretinal fluid or something that I'm really concerned about, OCTs is something that can really uh pick that up really easy.
- 6:40SPEAKER_01: But OCTs for me is also helpful in those individuals that have baseline geographic atrophy.
- 6:45SPEAKER_01: It gives me a better evaluation of what's going on in the outer segments of the retina, the the core capillaris, and the RPE, uh, so I can monitor their progression as it gets to orthophobia.
- 6:56SPEAKER_01: You know, I don't do as many fluorescent angiograms anymore.
- 6:59SPEAKER_01: I know that they still have a valued use.
- 7:01SPEAKER_01: I do do a fair amount of OCTAs, I can get a good idea of what's going on in the deeper segments of the retina.
- 7:09SPEAKER_01: And this can be both diagnostic and therapeutic.
- 7:12SPEAKER_01: When it comes to diabetic retinopathy, this is the leading cause of blindness in these individuals.
- 7:17SPEAKER_01: So for those that are type one, you really want to see them in the first five years or around adolescence.
- 7:23SPEAKER_01: Those that are type two, uh, because 25 to 30 percent of people will have retinopathy before they come in, you really want to see these people at diagnosis.
- 7:32SPEAKER_01: The Johnson Clinic did a very nice trial, and those individuals that had that that were known diabetic had 50%, they had uh 50% of them had sight-threatening problems and was not aware of it.
- 7:43SPEAKER_01: So oftentimes people will have a baseline disease before they come in for their first exam.
- 7:50SPEAKER_01: And so if someone has you know mouth disease, I'm not that concerned.
- 7:54SPEAKER_01: They don't progress as much.
- 7:55SPEAKER_01: I may want to see them annually or every two years, but I'm really concerned about those that have more severe diabetic retinopathy, those individuals, uh, because I know that if you have severe MPDR or PDR, the risk of vision loss can be as high as 50% within that first three to five years.
- 8:11SPEAKER_01: And those individuals I typically see a little more often.
- 8:15SPEAKER_01: Dilated funnel sample examination is really important, and I think the most important thing you do is grade the level of retinopathy.
- 8:22SPEAKER_01: I think that's the most important thing that we can do as a clinician to make sure we get that right, and that will help you to know how to follow that particular person.
- 8:30SPEAKER_01: Now, this is one case where I think wide field angiography is really helpful.
- 8:34SPEAKER_01: Um, no matter how good you are, it's really difficult to see featureless retina in the periphery.
- 8:39SPEAKER_01: A fluorescein angiogram can clearly show those ischemic areas, those peripheral neovascular membranes or neovascularizations that you that you may not see at the exam.
- 8:48SPEAKER_01: And so this is where I do want to make sure I do an FA to make sure I have the right grading.
- 8:53SPEAKER_01: Inherited retinal diseases to me is always the toughest.
- 8:56SPEAKER_01: And it's always, I'm always more looking for their signs and symptoms of something.
- 9:00SPEAKER_01: Those that may have nicelopia or visual field loss, or even central visual field loss, photophobia, nystagmus, any type of characteristic changes that I may I may notice on an exam.
- 9:12SPEAKER_01: So typically these individuals have signs and symptoms out of proportion to what their exams are sometimes.
- 9:18SPEAKER_01: Um, these are individualized uh screenings.
- 9:21SPEAKER_01: You really want to see them every one or two years once they once you have the diagnosis.
- 9:25SPEAKER_01: And you also want to make sure you take a good family history.
- 9:28SPEAKER_01: An exam is critical.
- 9:30SPEAKER_01: I think the OCT is really helpful to look at the outer segments uh depending on what's going on in the patient.
- 9:36SPEAKER_01: Fundus autofluorescence can be helpful, particularly if you're looking for liperfusion.
- 9:40SPEAKER_01: And even ERG is helpful if you think someone may have RP or even EOG for those that may have best disease.
- 9:47SPEAKER_01: I think the most thing that we can do as a clinician is make sure we do the genetic counseling and make sure we have molecular testing.
- 9:55SPEAKER_01: And if you suspect that there may be a systemic issue associated with this disease, you want to make sure that they get evaluated from that.
- 10:02SPEAKER_01: The one thing that I offer in my clinic is that I try to get them early on to a low vision specialist because I think it's easier for them to adapt to these types of um devices if they're young and when they see very well.
- 10:15SPEAKER_02: And that's really a nice uh overview of what's going on here.
- 10:20SPEAKER_02: Basically, we have two types of diseases.
- 10:23SPEAKER_02: We have the retinal vascular diseases, macular degeneration, diabetic retinopathy, and macular edema, and then finally macular uh retinal vein occlusions.
- 10:33SPEAKER_02: And those are very responsive to treatments where we can use anti-veggef intravitreal injections, and we're gonna talk about a whole host of approaches to that.
- 10:43SPEAKER_02: And then you have on the other side the inherited retinal diseases, where management is mainly supportive and making sure that they know how to adjust to the circumstances that they're living with.
- 10:56SPEAKER_02: And so, what we're gonna speak about moving ahead here is how we manage these patients because patients with these uh retinovascular diseases can do very well, maintain good vision, but unfortunately the treatments require frequent observation.
- 11:13SPEAKER_02: And much like Joe, I live off of the OCT, which is telling me whether or not my patient has fluid or they have macular edema, it's encroaching on the center of the vision, if their vision loss is from that fluid, or is it coming from atrophy?
- 11:28SPEAKER_02: I think it's very interesting to get uh you know a baseline of how our audience is doing.
- 11:35SPEAKER_02: So, what is the approximate five-year loss to follow-up rate for patients who are receiving the anti-VEGEF intravitreal injections?
- 11:45SPEAKER_02: Um, the four choices are near 30%, almost 50%, nearly 60%, more than 80%, and then my favorite, I don't know.
- 12:15SPEAKER_02: So the correct answer here is C.
- 12:18SPEAKER_02: Nearly 60% of patients stop taking anti-VEGF therapy and are lost to follow-up.
- 12:24SPEAKER_02: And this is very important because once these patients start to experience a visual decline, it's often not recoverable, particularly in the neovascular macular degeneration disease or what we call wet macular degeneration.
- 12:40SPEAKER_02: RVO, retinal vein inclusions, and diabetes are a little bit more forgiving on loss to follow up, but really the onus here is to make sure that we can carry our patients long term.
- 12:51SPEAKER_02: That involves either being on top of them all the time and making sure they're following up, or developing new therapies that last longer are ideally a combination of both.
- 13:02SPEAKER_02: And making sure our patients follow up is not just calling them up, it's getting them involved with resources that can maybe facilitate them if they have difficulty with transportation or there's financial issues and things like that.
- 13:15SPEAKER_02: And we're going to get into some of that stuff in the next few slides.
- 13:18SPEAKER_02: So these injections involve injecting right into the eye.
- 13:23SPEAKER_02: If you what do you what do I mean by injecting right into the eye?
- 13:26SPEAKER_02: If you take a needle and you poke it into a grape, it's exactly like that, except your eye's numb.
- 13:31SPEAKER_02: You're awake, um, you're alert, we give you a little topical uh numbing medication.
- 13:37SPEAKER_02: It sounds awful, but patients keep coming back for two reasons.
- 13:41SPEAKER_02: One, it isn't as awful as it sounds.
- 13:44SPEAKER_02: And number two, they usually experience a fairly immediate um improvement in visual acuity, whether that's qualitatively in the quality of their vision, they see fewer floaters, less distortion, greater contrast sensitivity, maybe even improved color vision.
- 14:00SPEAKER_02: But oftentimes they get improved functional vision, particularly if they're a new patient who's showing up and they're the first-time diagnosis, they can gain um anywhere between five letters and ten letters of visual acuity, which is going from 2030 all the way to 2020 or from 2050 to 2030, for those of you who don't follow letters like Joe and I do here.
- 14:25SPEAKER_02: Um, as you can see here, over time patients lose visual acuity when they're receiving injections.
- 14:34SPEAKER_02: Um, and oftentimes this is because they're getting fewer injections over time.
- 14:38SPEAKER_02: More injections are associated with better visual acuity and better fluid control.
- 14:44SPEAKER_02: As you can see here, starting visual acuity determines how well you're going to do.
- 14:49SPEAKER_02: Patients with the least amount of vision end up gaining the most amount of visual acuity, which is really encouraging for our patients because we have they now know that this medication is helping them.
- 15:03SPEAKER_02: I don't have to tell them it's helping them.
- 15:05SPEAKER_02: They get the injection and they come and tell me it's helping them, which is super satisfying for both of us.
- 15:11SPEAKER_02: Um, which brings us to our second learning objective here to develop individualized management plans for retinal disease that address our patient needs and access barriers.
- 15:24SPEAKER_02: Um, so we're going to explore the patient-first approaches to retinal disease management.
- 15:30SPEAKER_02: But first, let's check in with Natasha again.
- 15:35SPEAKER_00: In terms of shared decision making, I think sometimes we had it and sometimes we didn't have it.
- 15:41SPEAKER_00: I do remember times where, you know, I'd be sitting in the ophthalmologist chair and, you know, my doctor would be there and he'd he'd be talking, not just to my mom, but to me as well.
- 15:50SPEAKER_00: He'd be saying, you know, here's what we can do.
- 15:52SPEAKER_00: You know, here are options if we want to do this tempester, you know, X, Y, and Z.
- 15:57SPEAKER_00: Um, and so in those times, even though I didn't, again, I didn't entirely understand what those tempest were, you know, it was, it was a mutual conversation that we were all having.
- 16:06SPEAKER_00: Um, I do think there were definitely times when it was more simple like, we're gonna do this.
- 16:11SPEAKER_00: And I didn't really have a choice.
- 16:13SPEAKER_00: Um, and of course, I was just like, well, I'm a kid, so I have to do what, you know, the adults tell me to do.
- 16:19SPEAKER_00: Um, but you know, again, it was, it was kind of like, okay, I'd love to know, I'd love to understand why we're doing these things.
- 16:25SPEAKER_00: Um and, you know, and I think my mom was pretty good at like cluing me in, but there were definitely times where I had no idea what I was doing there.
- 16:33SPEAKER_00: I was just doing the tests that I was being told to do.
- 16:35SPEAKER_00: We never had, you know, issues of transportation or costs or anything.
- 16:40SPEAKER_00: Um, you know, it was always like one of my parents was going to take off work to get me to the eye doctor.
- 16:45SPEAKER_00: Um, when I was really young, when we lived in Alabama, we it was like a whole day because we had to drive almost two hours to get to my optometrist.
- 16:52SPEAKER_00: Um, so I again I do feel very lucky to have had that access.
- 16:57SPEAKER_02: So, Joe, Natasha brings up a couple of interesting points here.
- 17:00SPEAKER_02: One is really it takes a village, but in particular, it's not just on her because you know, she was a minor and had to be brought in.
- 17:09SPEAKER_02: I see this a lot in my pediatric retina practice.
- 17:12SPEAKER_02: You're gonna be able to inform us more about barriers that face adult patients for different reasons.
- 17:19SPEAKER_02: And this is an area of expertise that you've lectured on um around the country, um, in particular with regards to diabetes.
- 17:28SPEAKER_02: Can you tell us about that, Joe?
- 17:30SPEAKER_01: So, Dari, sure.
- 17:31SPEAKER_01: So, this is um something that's really near and dear to me.
- 17:34SPEAKER_01: Um, for one, it affects you know areas where I come from, south side of Chicago, for many years of rentlining where we were living in an area which was kind of depressed, and this area is still depressed today.
- 17:44SPEAKER_01: And it's really because of what we now know as social determinants of health.
- 17:48SPEAKER_01: And this can affect any population of people, uh, any any in any any demographic areas, but clearly um it can really affect a lot of things in how and and and what you do in life, whether it's medicine, whether whether it's education, whether it's working.
- 18:06SPEAKER_01: And I you know, there's a great definition that was put out by the World Health Organization.
- 18:11SPEAKER_01: I want to read this thing for you because you know I think they sum it up nicely.
- 18:15SPEAKER_01: It's the conditions in which people are born, grow, work, live, and age, and the wider set of forces and systems shaping the conditions of daily life, including economic policies, system development agendas, social norms, social policies, and political systems.
- 18:33SPEAKER_01: And that's a really good summary because sometimes how things are drawn up or policies are made, this governs on how people live and where they live.
- 18:43SPEAKER_01: And this has an impact on people's lives.
- 18:46SPEAKER_01: And and these things long term can create disparities, and these disparities unfortunately affect certain people more than others, particularly black and Hispanic patients.
- 18:56SPEAKER_01: And when it comes to what we do, we know that when you come from these sort of areas, there's also a downstream effect when it comes to vision.
- 19:03SPEAKER_01: They typically don't know about their health condition very well, they don't know that diabetes really affect the eyes.
- 19:11SPEAKER_01: Um, they don't know that high blood pressure is really important in managing when they have diabetes.
- 19:16SPEAKER_01: So health literacy is a big, big importance.
- 19:19SPEAKER_01: Also, where I come from, you know, there's a lot of mistrust and distrust just with any type of institutional uh uh type of programs.
- 19:28SPEAKER_01: And so they may delay their therapy.
- 19:30SPEAKER_01: We know that 50% of people that have diabetes are not coming in on it on a timely manner.
- 19:35SPEAKER_01: And because these are set up, they're coming in with more advanced disease.
- 19:40SPEAKER_01: I think for what we can do, we need to understand what the social vulnerability are for a particular area.
- 19:46SPEAKER_01: And what this is, that there's actually an index that a number that is given to a particular geographic location, and it shows that if that number is high, then the number of disparities are greatest.
- 19:58SPEAKER_01: And if you look at this on a map, it'll show you that diabetic macledema is at the highest at those levels, as well as certain disparities.
- 20:07SPEAKER_01: Um, access access to care.
- 20:09SPEAKER_01: You know, Natasha had a problem with access to care.
- 20:12SPEAKER_01: You know, when you have to travel more than 20 miles away from an office, we know that your care goes down.
- 20:17SPEAKER_01: When you present to an office, that goes down.
- 20:20SPEAKER_01: You're most likely not to get involved in clinical trials or just have exposure to certain things.
- 20:25SPEAKER_01: And when it comes to clinical trials, I think that it's really important for us as clinicians and and dairies, you're you you you've been involved with clinical trials for a long time, that we are creating diverse populations.
- 20:36SPEAKER_01: 90% of the DNA therapy that we have, and 90% of clinical trial data that we have is based on European ancestry.
- 20:44SPEAKER_01: And so unfortunately, we have to do sometimes phase four trials to really understand how it affects a certain population, and we really shouldn't have to do that.
- 20:51SPEAKER_01: I think we have to feel comfortable, we have to address our own implicit biases and um and try to get people involved in trials that are ordinarily not included to make sure that the medications that we're bringing for it are equally as effective as well as safe.
- 21:08SPEAKER_01: Now, when I think about all this, you know, I'm always coming back to diabetes because diabetes for me is the biggest thing that I see in my practice.
- 21:16SPEAKER_01: And as you said earlier, it's one of those things that is preventable.
- 21:19SPEAKER_01: And yet we still have low rates of screenings in the black and Hispanic populations.
- 21:24SPEAKER_01: And this can be of a variety of reasons.
- 21:26SPEAKER_01: Either lack of understanding, socioeconomic, and financial barriers.
- 21:30SPEAKER_01: We know that if you are a certain mean of both education and financially, they're less likely to present uh to an ophthalmologist.
- 21:40SPEAKER_01: It's very time consuming.
- 21:41SPEAKER_01: Typically, when it comes to diabetics, this is the working age population, it's very difficult to take off time to come to the doctor each time.
- 21:48SPEAKER_01: And transportation is an issue because sometimes it may be only one um one vehicle uh in the office, and they may not be on a transportation line that can take them from one place to another.
- 21:58SPEAKER_01: So we know that rural.
- 22:00SPEAKER_01: Areas also have an issue.
- 22:01SPEAKER_01: Also, in the rural areas, there are health qualified centers, and only 70% of those centers will have a eye lane.
- 22:07SPEAKER_01: So they may never see an ophthalmologist on time, at least on a timely manner.
- 22:13SPEAKER_01: And again, I think the most important thing for our patients who logistically don't speak um English, it's really good to give them a literature in their own language so they can understand really what's going on.
- 22:24SPEAKER_01: I think it's our job to help our patients prioritize their eyes so they know that the importance of really what we do.
- 22:32SPEAKER_01: 26 to 28% of individuals that are black or Hispanic are less likely to seek an ophthalmologist than a non-white Hispanic.
- 22:41SPEAKER_01: When we look at the prevalence of diabetes, blacks and Hispanics present at a much higher rate of diabetes.
- 22:49SPEAKER_01: Their rate of progression uh tends to be uh uh faster, and they typically present with a higher incident of a vision-threatening uh diabetic eye disease.
- 22:59SPEAKER_01: And this are these are really, really important because we know that these again are preventable things, and typically when they come in, they have already reached a level where the best thing we can do sometime is stabilize a vision versus what you said earlier, take them from 2040 to 2020.
- 23:16SPEAKER_01: And then lastly, you know, I think social terms of health can also affect individuals with macular uh degeneration.
- 23:22SPEAKER_01: We know again that you know having come from a lower socioeconomic status um has also been associated with a higher incident of having uh AMD and also a poor visual uh prognosis, and that has to do with lower education, lower income, as well as just the neighborhood deprivation.
- 23:39SPEAKER_01: Uh, there's a higher odds of you um having uh decrease in vision from AMD if you're divorced or if you're widowed or you live by yourself.
- 23:47SPEAKER_01: I do find that my patients that have a strong support system, particularly if they have children, uh, that's really helpful because sometimes they're older people and the only people they had for a long time was their spouse.
- 23:58SPEAKER_01: And now their spouse now are is not there to help them uh take care of themselves.
- 24:03SPEAKER_01: Uh the one thing that I always talk about patients with, and that's the one modifiable risk factor, is really smoking and alcohol.
- 24:10SPEAKER_01: Uh, we know that these things can also increase your risk for it, more advancing forms of uh of macular degeneration.
- 24:16SPEAKER_01: So health style modification can be very helpful uh uh in this population.
- 24:21SPEAKER_02: So, Joe, thanks for highlighting all of that.
- 24:24SPEAKER_02: And when you come to this slide, you see it's a team-based approach for retinal disease management.
- 24:29SPEAKER_02: Basically, everyone's involved.
- 24:31SPEAKER_02: Here we have a bunch of uh medical uh technicians, uh, caregivers, ophthalmologists, optometrists, social workers, but your family, your transportation people, um, you know, uh it moves even beyond that to like your social services, all of that plays into how you're going to do when you have one of these chronic diseases for which we have um good treatments available.
- 24:58SPEAKER_02: So that kind of leads us into getting our audience involved again with another scenario.
- 25:05SPEAKER_02: A 72-year-old woman with wet macular degeneration has received three monthly anti-VEGF injections with anatomical improvement.
- 25:14SPEAKER_02: The fluid went away.
- 25:15SPEAKER_02: However, she tells you she's considering stopping treatment because she feels overwhelmed by the frequent visits and says, I don't think this is sustainable for me.
- 25:24SPEAKER_02: She lives alone, relies on her daughter for transportation, and expresses concern about being a burden.
- 25:30SPEAKER_02: What is the most appropriate next step?
- 25:34SPEAKER_02: Um, choice A is to reinforce that these visits are and injections are important.
- 25:39SPEAKER_02: Choice B is transition to a fixed extended interval regimen.
- 25:43SPEAKER_02: Choice C is to explore her concerns in greater depth, including assessment of logistical and psychological barriers.
- 25:50SPEAKER_02: D is to document her reluctance, but firmly recommend staying the course.
- 25:55SPEAKER_02: And E, of course, my favorite.
- 25:57SPEAKER_02: I don't know.
- 26:28SPEAKER_02: So Joe, I'm gonna turn this over to you.
- 26:32SPEAKER_02: Focused action and physician competence.
- 26:35SPEAKER_01: You know, Darius, I think this is really important.
- 26:37SPEAKER_01: You know, we always want to leave people with things that they can immediately integrate into their practice.
- 26:42SPEAKER_01: And I think that there's a lot for us to learn, and a lot that I've learned really from my patients, and things that I've really learned is really humility.
- 26:49SPEAKER_01: You know, patients want to understand that you have a certain feeling for them.
- 26:54SPEAKER_01: Um, this is really just going back and just and just making a communication with your patient.
- 27:00SPEAKER_01: Um, and and a good way to do this here is really taking an enhanced uh history.
- 27:05SPEAKER_01: At my EMR, we have a little area where I'm able to put down something about the patient, maybe where they're from, an activity they like, if they're a golfer.
- 27:12SPEAKER_01: And so when they come in, I could have a conversation with them about the things that we've talked about before.
- 27:18SPEAKER_01: And this kind of resonate because they think that you, you know, it helps them understand that that's a great communication between you and the patient.
- 27:27SPEAKER_01: One thing I've really learned from my patients is that communication is really, really critical.
- 27:31SPEAKER_01: Um you can do everything right for a patient, you can make the right diagnosis, institute the right therapy, but if the patient don't feel like they're heard or understood, they feel like the care is just not as good as they had hoped, and they feel like um they want to go someplace else.
- 27:46SPEAKER_01: So this also increases adherency uh to the office, which sometimes drops off, particularly in populations which um are much more difficult to treat.
- 27:55SPEAKER_01: Understanding the culture of patients, I think, are um are critical.
- 27:59SPEAKER_01: Just understand that the different aspects of patients' lives uh helps us to be a better communicator.
- 28:07SPEAKER_01: Uh and the better you can communicate with a patient, I think, the more they can understand.
- 28:11SPEAKER_01: And then this this tends to lead into a part where you can educate them better about their disease process.
- 28:17SPEAKER_01: You know, Mrs.
- 28:18SPEAKER_01: Johnson, you know, this your A1C last year is 25.
- 28:21SPEAKER_01: This year is 7.5, we're very happy, you know, how you're doing.
- 28:24SPEAKER_01: I mean, having that discussion with them, I think really, really means a lot.
- 28:28SPEAKER_01: And again, passing information out uh uh about their condition, every new patient in my office that they get a brochure.
- 28:35SPEAKER_01: And if we have it um in the Spanish uh language and and we'd like to share with that or videos that we can direct them to, I think is really, really helpful.
- 28:43SPEAKER_01: But cultural humility piece is something that I think we all can do.
- 28:47SPEAKER_01: Um, you can practice this with you know your colleagues, your residents, and your fellows, and you can learn from you know how you project your ways and how you how you deal with your own implicit bias and microaggressions and things that you may not be aware of.
- 29:03SPEAKER_01: I think we all need to do a better job with our patients.
- 29:06SPEAKER_01: And so these are things that we can institute in our in our practice to be uh much more effective uh communicators.
- 29:15SPEAKER_02: Joe, thank you very much for that.
- 29:17SPEAKER_02: Um, one of the things that the very first question I always get asked is, how long am I gonna be on this therapy?
- 29:25SPEAKER_02: And for diabetes and RVO, I really don't know the answer to that question.
- 29:30SPEAKER_02: I usually say, well, we're gonna treat you for a few months and then we're gonna see how you respond.
- 29:35SPEAKER_02: But for wet macular degeneration, it's often the case that they're gonna be on the intervention for as long as they live.
- 29:43SPEAKER_02: So let's take a look at a short patient case.
- 29:46SPEAKER_02: This is a 77-year-old man with uh wet macular degeneration, um, and he presents with visual acuity that's really good, 2025 in both eyes.
- 29:57SPEAKER_02: He had received one injection in the right eye while he was traveling, and he should when he returned back to Stanford, um, he came in for uh to establish care with us, and he had bilateral neovascular macular degeneration.
- 30:12SPEAKER_02: And what I want you to focus on in this uh case series here is that over 16 years he receives a whole lot of injections in both eyes.
- 30:22SPEAKER_02: And throughout that entire time, when we look at the OCT, which is basically how thick or how thin the retina is, and for our cases that's representative of the amount of fluid, he has evidence of disease activity based on the thickness of the retina throughout the entire time that he's seeing me, despite all of these injections in his eyes.
- 30:46SPEAKER_02: But the reward is he maintains visual acuity, but it shows that this patient is at risk for losing that vision if we were ever to stop those injections.
- 30:58SPEAKER_02: And I'm just going to kind of get into it.
- 31:00SPEAKER_02: They started off with relatively good vision, 2025 in both eyes, and the OCT on the right-hand side is showing us that there's fluid and thickening for different reasons in both eyes, and this is 16 years ago.
- 31:15SPEAKER_02: And then the patient receives a whole bunch of injections, monthly injections for two years, gets good vision.
- 31:21SPEAKER_02: But as you can see at the bottom of the uh the photograph here, that there's still evidence of ongoing disease activity.
- 31:31SPEAKER_02: And then as we move along, seven years in advance, the patient still has pretty good vision.
- 31:36SPEAKER_02: You can drive in all 50 states if you're at least 2040 in one eye or better.
- 31:41SPEAKER_02: And this patient here is 2040 and 2030, but they've been still receiving a bunch of injections.
- 31:47SPEAKER_02: They did have an inflammation about six years earlier and then recovered quite well from that.
- 31:52SPEAKER_02: And then here you see as we move into the 2020s, the patient is still having pretty dramatic fluid in both eyes, and yet still has good vision.
- 32:04SPEAKER_02: And as we get into February 2024, it looks basically the same from two years earlier.
- 32:09SPEAKER_02: And again, we switched over to one of the newer second-generation molecules, ferissimab, which we thought could get us a lot longer out.
- 32:17SPEAKER_02: And he was able to move from four-week injections to eight-week injections, but continued to have fluid on eight-week injections.
- 32:25SPEAKER_02: And then here we are in 2026.
- 32:28SPEAKER_02: The patient has received about 150 injections in both eyes, which is 300 injections total, and yet, and continues to have disease activity in both eyes, but has spectacular vision, 2040 and 2030.
- 32:42SPEAKER_02: And this gentleman is now in his low 90s and uh is able to read without uh any extraneous aids.
- 32:51SPEAKER_02: And so, overall, this is a pretty good win case, but it highlights the problem.
- 32:56SPEAKER_02: You know, this patient is has to come back or is going to lose vision.
- 33:00SPEAKER_02: And Joe, you've seen a bunch of cases like this.
- 33:02SPEAKER_02: Um, you want to briefly comment on that?
- 33:05SPEAKER_01: Yeah, there is a great case.
- 33:07SPEAKER_01: Um, this is not uncommon for us to have persistent swelling uh for patients.
- 33:10SPEAKER_01: You we know we do know that some patients can tolerate fluid better than others.
- 33:15SPEAKER_01: Typically, you know, they tolerate subretinal fluid better than intra retinal fluid.
- 33:18SPEAKER_01: You look at all our data, uh, typically people with intra retinal fluid would have a progressive decrease in vision over time.
- 33:24SPEAKER_01: It's interesting in this case here that I do think, and particularly in the right eye, um, that everything is stable and the fluids tend to increase after the inflammatory event.
- 33:35SPEAKER_01: And so there is some surface retinal disease.
- 33:37SPEAKER_01: And so as a clinician, we have to determine if that ERM um or any other traction you may have, is that a part of the process?
- 33:45SPEAKER_01: And it's really hard for us sometimes to know if this is an extraditor component or if it's or if it's just a or just a cavitation from other other lining uh diseases.
- 33:55SPEAKER_01: Typically, what I do in these patients, and if we've already introduced uh the second generation, I will go ahead and push those patients out uh slowly and see if it fluctuates.
- 34:04SPEAKER_01: So I'm more concerned about fluctuating fluid, but I definitely agree that long-term maintenance at some interval um is better than a PRN dosing.
- 34:13SPEAKER_02: Thank you.
- 34:14SPEAKER_02: Which brings us to our third learning objective to identify the mechanistic link between blood retinal barrier dysfunction and the rationale for emerging therapies in retinal disease.
- 34:25SPEAKER_02: But before we go there, we're gonna hear from Natasha one more time.
- 34:32SPEAKER_00: So my visual acuity is pretty bad, right?
- 34:35SPEAKER_00: Um, obviously I can wear glasses.
- 34:39SPEAKER_00: Um that's only gonna do so much, to be honest.
- 34:42SPEAKER_00: Like obviously it's gonna correct my vision a little bit.
- 34:45SPEAKER_00: It helps me read up close, but I can't see things from a woman.
- 34:48SPEAKER_00: And that's like something that really nothing is going to fix.
- 34:51SPEAKER_00: And so, you know, I'm I'm glad that my optometrist and my ophthalmologists have been able to help me like as much as they can.
- 34:59SPEAKER_00: But I think kind of the extra step is like, okay, we've corrected everything we can on our side.
- 35:05SPEAKER_00: What can we do to like help you just what you can't see?
- 35:09SPEAKER_00: And so growing up, it was like, um, you know, here's like a little monocle that you can use, or here's like basically a binoculars that you can take with you.
- 35:18SPEAKER_00: Um, and here are like accessibility tools to help you, um, especially like throughout school, and um having those resources and even just, you know, having doctors to tell me about things that I didn't even know was like a resource I could use um has been really helpful.
- 35:32SPEAKER_00: And to be honest, a lot of it now is just things I find on my own.
- 35:36SPEAKER_00: Um, I'm constantly trying new accessibility tools.
- 35:39SPEAKER_00: I just I have an app on my phone that like you can point it at a crossbook signal and it'll actually tell me when I can cross the street safely.
- 35:47SPEAKER_00: And like that wasn't like something I found a couple of years ago after like kind of risking my own life every time I cross the street beforehand.
- 35:55SPEAKER_00: Um and so I think, you know, I think if if doctors can, you know, take that extra step of like, all right, here's what we're gonna help you with, um, with you know, the things that you can't see, just like really important because again, it's it's all it's all part of your treatment plan, even if it's not like explicitly medical, right?
- 36:13SPEAKER_00: So yeah.
- 36:15SPEAKER_02: I think this is super useful information for us.
- 36:19SPEAKER_02: Every year I find out if my patients have gotten their spectacles updated or replaced.
- 36:24SPEAKER_02: And then the second thing is I find uh if they're plugged in with a primary care ophthalmologist to manage something simple like dry eye, which is not simple to manage, but from a retina disease perspective, it seems a lot easier sometimes.
- 36:38SPEAKER_02: Um how do you go about trying to uh improve your patients' lives?
- 36:43SPEAKER_01: You know, we have um brochures and nice communications um with our low vision specialists.
- 36:50SPEAKER_01: And, you know, I am not a low vision expert by any means, and I I let them know in the in the practice on why they're going there because they need something beyond the scope of what I can provide.
- 37:00SPEAKER_01: And they have all you know, once they go through a complete evaluation, they have all sorts of things which may be helpful for patients.
- 37:06SPEAKER_01: Some um unfortunately may not be approved by insurances.
- 37:09SPEAKER_01: I think that's the that's the that's the barrier.
- 37:11SPEAKER_01: You know, there are things out there, then how can they get access to it?
- 37:14SPEAKER_01: But some of the federal funded uh programs uh will help them uh get a closed caption, you know, monitor.
- 37:22SPEAKER_01: Um, have them, you know, the even I've had some patients even using um glasses that would take a photograph of the photo and it reached to them.
- 37:31SPEAKER_01: Um, and that has been really helpful.
- 37:32SPEAKER_01: So there's all these things out there that I may not be aware of or know don't really know how to train people on, um, but I think that we wait too long to get people involved with the low vision specialist.
- 37:45SPEAKER_02: Thank you, Joe.
- 37:46SPEAKER_02: So now we're gonna move on to like the science-y aspect of this and talk about the link between pathophysiology and emerging therapeutics, which sounds like a lot.
- 37:55SPEAKER_02: So the eye is made up of two blood retinal barriers, and you can think of these as special doors beyond which you need a key card to get past if you're not inside the eye.
- 38:07SPEAKER_02: Um, the first one is called the inner blood retinal barrier, and it's located inside the retina.
- 38:12SPEAKER_02: And the second one is the outer blood retinal barrier, which is between the retina, and then another layer of blood vessels, which is called the choroid.
- 38:21SPEAKER_02: Um, within the retina, it's actually uh at the tight junctions of these retinal capillary endothelial cells, and then the one between the retina and the choroid is again these tight junctions between the retinal pigment epithelial cells.
- 38:37SPEAKER_02: There's a whole bunch of cells that work to uh make this happen.
- 38:41SPEAKER_02: I'm not going to get into that.
- 38:42SPEAKER_02: There's two different blood sources.
- 38:44SPEAKER_02: One is the central retinal artery, which eventually traces its way all the way back to the internal carotids and then back all the way to the heart.
- 38:53SPEAKER_02: And the other one is coming from the choriocapillaris, which is this multi-layered uh unit underneath the retina, which kind of acts like that little fan in your computer to cool off the retina.
- 39:04SPEAKER_02: And the inner blood retinal barrier is associated with a whole bunch of pathologies.
- 39:09SPEAKER_02: Most often we think about it with diabetic and the retinal vein occlusions, whereas the outer blood retinal barrier is associated with a different kind of pathologies, such as wet macular degeneration and the pigment epitheliopathies and central serous chorio retinopathy.
- 39:28SPEAKER_02: And that's a lot to kind of keep track of.
- 39:30SPEAKER_02: As we're moving ahead, there's basically four main sustained delivery approaches.
- 39:36SPEAKER_02: This is how we move from four weeks to eight weeks, twelve weeks, potentially 16 weeks, and even longer, maybe six months.
- 39:44SPEAKER_02: And so there's four different things that we're going to be talking about in high level second generation anti-VEGF agents, kind of like a surgical refillable reservoir that you have in your eye, TKIs, which are called uh tyrosine kinase inhibitors, which is kind of like an anti-VEGF.
- 40:01SPEAKER_02: Um, and then finally gene therapy, which is kind of like a uh genetic modification of uh anti-VEGF.
- 40:10SPEAKER_02: Um, so Joe, um, can you take us through these second-generation molecules?
- 40:16SPEAKER_01: Sure.
- 40:17SPEAKER_01: Um, and I think this is really, you know, have revolutionized at least what we do for patients.
- 40:21SPEAKER_01: I mean, we've been using anti-VEGF medications, which is a medicine to decrease permeability in the eye or in abnormal blood vessels.
- 40:30SPEAKER_01: And the problem with that is that people needed repeat injections, oftentimes every four to eight weeks.
- 40:34SPEAKER_01: And like you said earlier, people drop off over time.
- 40:37SPEAKER_01: And so these subtherapeutic uh points in patients' lives where they fluctuate with the variability of the OCD going up and down, over time they lose vision, they have fibrosis, and you cannot get that vision back.
- 40:48SPEAKER_01: Well, with the second generation, I think these are more durable drugs.
- 40:52SPEAKER_01: So, for example, with a fluorose of HD, this is a this this dose is four times stronger than the dose that we had the second generation.
- 41:01SPEAKER_01: And this higher molar dose is allowing patients 80% are going out, you know, more than 12 weeks, and sometimes even uh 16 and 20 weeks.
- 41:10SPEAKER_01: Ferissimab was the first bi-specific molecule that we had, and so up to this point, everything worked on some of the exact same factors, which is really vascular endothelial growth factor.
- 41:21SPEAKER_01: And this were also had an has an effect on anch too, which is also important for inflammation as well as permeability.
- 41:28SPEAKER_01: And again, we saw patients in the trial going out 16 weeks, and it seems like these smaller molecules tend to tend to be more associated with um certain uh inflammatory events that and it was very difficult for us to get over that hump.
- 41:44SPEAKER_01: But it seems like we've come to a point where at least the second generation's uh uh medications are well tolerated, they're very low risk of inflammation, very low risk for um vasculitis, and it has really, really improved the quality of lives of my patients because they have decreased the the burden of therapy for coming in more often, uh needing um more frequent treatments.
- 42:08SPEAKER_02: Thank you, Joe.
- 42:09SPEAKER_02: So that's a nice introduction to get us into our ongoing problem, which is we have these patients with you know chronic disease, and we know we can keep them on good visual acuity if we get them coming in and we continue to give them injections.
- 42:27SPEAKER_02: So this is a patient that I inherited from one of my junior fellows who was on the East Coast, and when this patient moved out here to the West Coast, she came in at almost 70 with type 2 diabetes and had received 43 injections with the other physician of a flibercept in both eyes.
- 42:44SPEAKER_02: Uh relatively good vision, uh, 2050 and 2040, um, relatively poorly controlled with a uh elevated hemoglobin A1C.
- 42:54SPEAKER_02: Um, and then overall, you know, had some signs of non-proliferative diabetic retinopathy.
- 43:00SPEAKER_02: And it's very interesting.
- 43:01SPEAKER_02: If you take the last picture of the patient that I showed you on the last case report in the right eye, and you look at the first picture of the OCT here, that was wet A and V, and this is diabetic macular edema.
- 43:14SPEAKER_02: They look very much alike.
- 43:16SPEAKER_02: And it goes to show you that when you're looking at the OCT, unless you see atrophy or you see drusen that are giving away the game, there's a lot of findings that kind of overlap in this disease, but it shows you why the anti-VEG F works across multiple different classes here.
- 43:32SPEAKER_02: So here, patient shows up 2030 in the right eye, 2020 in the left eye, there's an obvious distortion in the right eye, and had received in that time frame 43 aphibriceps in each eye.
- 43:46SPEAKER_02: A couple of months later, still 2030, still 2020 in the right and left eye, respectively.
- 43:52SPEAKER_02: And then we switch over to the second generation parissimab anti veg F agent, the so called bispecific model.
- 44:00SPEAKER_02: Molecule, which has both an anti-VEGF and an anti-ange effect, which works to stabilize the capillaries.
- 44:07SPEAKER_02: You see that stabilization didn't really help the OCT a lot, which is not shocking because sometimes when you get these chronic macular edemas, the cyst just becomes recalcitrant, and we're really trying to maintain the photoreceptor health as opposed to really push out the fluid.
- 44:23SPEAKER_02: But you see, the left eye is very responsive, still receiving 12 injections of aflicept in 2024.
- 44:30SPEAKER_02: Switch back in the right eye to aflibrecept, but the higher dose one.
- 44:35SPEAKER_02: And then in the left eye continued with uh 10 monthly uh aflibercept injections.
- 44:41SPEAKER_02: And you can see monthly is kind of a ballpark approximation because patients can't make it every month, or they're vacationing, or just how it works out.
- 44:51SPEAKER_02: Maybe they're sick.
- 44:52SPEAKER_02: Then finally, 2026 rolls around and we're alternating with uh every other month where the patient has figured out a way to get the insurance payer to give them a flibricept every other month and ferissimab on the off months, and it's the only patient that had this going on.
- 45:13SPEAKER_02: I don't know how she got this going, but anatomically, maybe there's a little bit of improvement in the right eye.
- 45:19SPEAKER_02: The left eye is fairly stable in between dehydrates.
- 45:23SPEAKER_02: Visual acuity, great.
- 45:25SPEAKER_02: 2030 in the right eye, 2020 in the left eye.
- 45:28SPEAKER_02: And again, as you see, there's not a lot of push in the right eye.
- 45:32SPEAKER_02: Over time, sure, it's improved a little bit, but continues to have that large cyst right near the center of the vision.
- 45:38SPEAKER_02: As 2026 has rolled around, the patient has received close to 80 injections in the right eye, and uh slightly more than 80 injections in the left eye to achieve good vision, 2030 in both eyes, and a modest improvement in anatomy in the right eye and a stabilization of anatomy in the left eye.
- 45:59SPEAKER_02: And at the end of the day, this is kind of par for the course with a lot of our patients.
- 46:05SPEAKER_02: What did you say, Joe?
- 46:07SPEAKER_01: Yeah, dear, I think this is another you know great case, and congratulations to you for over the number of years, have not lost any vision.
- 46:14SPEAKER_01: Um, and that's really great.
- 46:16SPEAKER_01: But the burden at the burden for her has been great.
- 46:18SPEAKER_01: Um, one thing that I typically do with my diabetics that have persistent uh swelling, and it's important for me to figure out what the driver is.
- 46:26SPEAKER_01: Is it a is it a VEGF-driven disease or is there anything else like an inflammatory event?
- 46:31SPEAKER_01: And so sometimes what I do, um I want to challenge them with the steroid and just see if the uh cysts uh collapse.
- 46:38SPEAKER_01: And we have two types of steroids which are approved for a diabetic manic or edema.
- 46:43SPEAKER_01: Um if the if the fluid resolves, and I know that there's an inflammatory component, and they I think they do very well with a longer-acting uh durable drug that um can keep them stable.
- 46:55SPEAKER_01: If things are stable, um which means they don't change with the steroid or with the anti-Veg F injections, these people may just have chronic swelling.
- 47:02SPEAKER_01: And so I typically will continue to extend them out, and what I'm looking for is fluctuating fluid.
- 47:08SPEAKER_01: Uh, but again, here, you know, this patient has actually done fairly well, number of injections, and this is a burden that we typically see with our patients.
- 47:15SPEAKER_01: I think your patients love you because it's really difficult uh for patients to come in this much uh without getting injection fatigue.
- 47:24SPEAKER_02: Thank you, Joe.
- 47:25SPEAKER_02: Um my uh technicians uh don't love me as much as you do, having called these patients up and bring them back in.
- 47:33SPEAKER_02: But it's very satisfying when they do well.
- 47:35SPEAKER_02: Which brings us to our next and final audience response question.
- 47:39SPEAKER_02: And this is highlighting the role of blood retinal barrier, which is a central pathophysiologic feature of diabetic macular edema, which is contributing to the vascular leakage and the retinal thickening.
- 47:51SPEAKER_02: An investigational agent, MK3000, in development for DME, is designed to address blood retinal barrier dysfunction through which of the following mechanisms?
- 48:02SPEAKER_02: Choice A is activation of WINT signaling and retinal vasculature, choice B is long-term intraocular veg suppression via viral vector-mediated gene transfer.
- 48:14SPEAKER_02: Choice C is complement inhibition to reduce inflammatory mediated retinal damage.
- 48:19SPEAKER_02: Choice D, dual inhibition of veg FA and ANG2 to stabilize pathologic neovascularization, and again, my favorite, I don't know.
- 48:47SPEAKER_02: In this case, the answer is choice A.
- 48:50SPEAKER_02: Um, MK3000 is a novel Wint signaling um activated for retinal vasculature, and it's thought to help uh with the management of the blood retinal barrier.
- 49:03SPEAKER_02: So Joe, as we're looking ahead, and we've got a lot of emerging agents coming here, we've got the Wint agents, and we've got a whole bunch of uh named chemicals here that it's hard to really keep track of.
- 49:17SPEAKER_02: Some of them are gene therapies, um, some of them are uh dual inhibition agents.
- 49:22SPEAKER_02: Um, what are you thinking about and how do you talk about these with your patients as we move ahead?
- 49:29SPEAKER_01: You know, really, I'll just sum the write this up, you know, in in the more simple terms.
- 49:33SPEAKER_01: You know, we have barriers to therapy, um, and we have different routes of administration to address certain barriers.
- 49:41SPEAKER_01: You know, historically we've had a very difficult time to have vectors in the eye and and cross the internal native membrane.
- 49:47SPEAKER_01: So our earlier studies have been was shown to um develop gene therapies, and these are gene therapies where biofactories are created, they get incorporated into your own retinal, your retinal cells, and they make the same anti-VEGF injections that we give on a monthly basis.
- 50:01SPEAKER_01: So the goal is to have sustained release so you don't have the fluctuations in vision to maintain that vision long term.
- 50:07SPEAKER_01: And so and so the subretinal space and superproto space were two things that was very easy for us where we could put medicine and we know we can get an effect.
- 50:16SPEAKER_01: And then but the difficult part was trying to go past the internal linear membrane, but now we have vectors that we can inject in the eye, and these are all in clinical trials that can do the exact same thing.
- 50:26SPEAKER_01: They can make the same uh type of molecules that inhibits uh VEGF uh uh uh suppression long term.
- 50:34SPEAKER_01: And then you have, you alluded to earlier, something called TKIs.
- 50:37SPEAKER_01: And these TKIs are little small molecules, they're also given in the intravitral space.
- 50:43SPEAKER_01: Um, I'm sorry, in intraventral through various mechanisms of various delivery platforms.
- 50:49SPEAKER_01: And this is the first time that we have something maybe a little more novel, right?
- 50:53SPEAKER_01: The everything we had before really blocked VEGF.
- 50:56SPEAKER_01: Well, this actually goes intracellular.
- 50:58SPEAKER_01: Um, they have an effect a little bit more downstream, so you can decrease permeability.
- 51:03SPEAKER_01: Um, the difference between these is that in gene therapy, we're hoping that in some cases that it may be one and done.
- 51:10SPEAKER_01: And TKIs, uh, we're hoping to address durability, maybe extend them six months, maybe nine months.
- 51:18SPEAKER_01: I think no matter what we have, there, you know, these are so early in clinical trials, there's still a lot uh to be learned, there's a lot to be gained.
- 51:25SPEAKER_01: We do have people out, you know, five years on some of these trials, but safety, I think, is really going to drive the discussion along with efficacy.
- 51:34SPEAKER_01: But I think safety is going to be the most important thing.
- 51:36SPEAKER_01: When it comes to gene therapy, you know, there's still this black box which we don't know how people are gonna do long term.
- 51:43SPEAKER_01: And I think for all of us, we're very excited about it.
- 51:45SPEAKER_01: One thing for sure is that in the phase, in the phase one, two of trial so far, um the durability of these drugs has really decreased the number of uh of injections that patients required.
- 51:59SPEAKER_01: Um I would like to get your you know, your thought.
- 52:01SPEAKER_01: You know, once these drugs are approved, if they ever get approved, um what what are you most concerned about with these uh newer medications that we're looking at in clinical trials?
- 52:12SPEAKER_02: Thank you, Joe.
- 52:13SPEAKER_02: Um so basically, when we're looking at gene therapy, right, um you're giving what we in the retina community are referring to as a gain of function.
- 52:23SPEAKER_02: So you're adding something that we didn't have before, and what you're adding to the eye is this anti-veg F long-term production um asset inside the eye.
- 52:35SPEAKER_02: And since you're genetically modifying the cells, this can go on and on and on.
- 52:40SPEAKER_02: But it's predicated on two things, really.
- 52:42SPEAKER_02: One is that it goes to where you want it to go, and that's the vector, which is the in this case, it's an AAV viral vector, AEV2, I think, is often used.
- 52:56SPEAKER_02: But when you talk to the scientists, and at Stanford recently, we've had a string of people speaking on gene therapy, and you ask them about you know, where does it go else?
- 53:06SPEAKER_02: Where else does it bind?
- 53:08SPEAKER_02: They have very limited knowledge of where it binds.
- 53:10SPEAKER_02: And so what they call off-target events are unpredictable inside the eye.
- 53:17SPEAKER_02: When you ask them about where it can go outside of the eye, they have no idea.
- 53:21SPEAKER_02: And these binding uh domains where the vector can bind to are not well known which cells throughout the body can actually have this.
- 53:33SPEAKER_02: So maybe you put it in the eye and it's very specific for a cell on the retinal pigment epithelium, but it's also possible that it somewhere in the ovary it has that.
- 53:42SPEAKER_02: You may not want to have your cell expressing in the ovary, which is why the safety concerns that you're alluding to, even though we have five-year data, it may be that at 10 years we have a different problem.
- 53:54SPEAKER_02: And I don't like that unknown aspect of it.
- 53:57SPEAKER_02: So I like the ability to shut off something, which is why I like the concept of a TKI or a refillable reservoir or a second generation agent as opposed to a more permanent sort of thing that I might not be able to turn off when I need to.
- 54:13SPEAKER_02: But as we move ahead here, and I no longer do incisional surgery, so I make a referral out for any of my patients who want the port delivery system.
- 54:23SPEAKER_02: Um, but can you tell us about that or if you've had any experience on that?
- 54:28SPEAKER_01: Yeah, you know, I think the port delivery system is a really good bridge.
- 54:31SPEAKER_01: It uses uh it uses novice, we already know.
- 54:33SPEAKER_01: It uses a high dose randomism app, which is the first approved therapy to treat both neovascular AMD as well as diabetic macal edema.
- 54:40SPEAKER_01: And the goal is really to put this reservoir in the eye, it's sewn into the sclera, and the medicine is given right into the right into the vitreous, and it's the the goal is to have a longer projection or continuous dose of therapy for about six months.
- 54:55SPEAKER_01: And what was so interesting about the phase three and even the extension portal trial is that individuals, uh about 95% of individuals did not require a refill before, I'm sorry, did not require a supplement injection before the refill.
- 55:11SPEAKER_01: And this was compared to monthly random bisoman.
- 55:13SPEAKER_01: These were treated experienced eyes, they had a mean of three to five injections before they could have the implants of these eyes already were treated previously that showed that they had a response to anti-VEGF therapy.
- 55:25SPEAKER_01: But it was really surprising to me that over that course of five years, uh they were able to maintain vision with a stable OCT.
- 55:34SPEAKER_01: And we typically see much more fluctuations in this population of people.
- 55:39SPEAKER_01: Now, with that being said, it's surgery.
- 55:41SPEAKER_01: And I think that's really what limits is used.
- 55:43SPEAKER_01: You know, I think that there's been a lot of modification when it comes to how to put the device in.
- 55:48SPEAKER_01: But clearly, if there's someone that has ocular surface disease, or if they have a thin conjunctival or T-non's capsule, or they are eye rubbers, these are people that may not be the best candidates for this particular uh device.
- 56:01SPEAKER_02: Which kind of brings us back to the tyrosine kinase inhibitors, right?
- 56:05SPEAKER_02: Before we complete here, and this is a big year.
- 56:08SPEAKER_02: We just had uh the first pivotal trial readout, um, which was a successful outcome for acetinab um for the tyrosine kinase inhibitors.
- 56:19SPEAKER_02: And we're going to have probably two more readouts for the vorolanib later this year.
- 56:24SPEAKER_02: And so these are small molecules that are taken up intracellularly, and then they kick in variably over four, eight, twelve weeks, and then theoretically, um at least in the case of vorolanib, um, and it's been demonstrated now in a superiority trial that acetineb can give you this long-term uh suppression of VEGF.
- 56:50SPEAKER_02: And it has two advantages theoretically over either the surgical implant or the gene therapy approach, in that one, you don't have to have surgery, which is nice, and then the second advantage is you don't have to worry about the off-target effects and long-term theoretic uh problems affiliated with gene therapy.
- 57:14SPEAKER_02: Um, we're gonna learn more about this in the coming weeks as uh this data is presented at the Macula Society, and and we learn more about uh the totality of this data.
- 57:25SPEAKER_02: Yeah, it's exciting times to be here in Retina today in 2026.
- 57:30SPEAKER_02: We're on the cusp of really kind of dramatically transforming our patients' lives.
- 57:36SPEAKER_02: But that's all the time we have today.
- 57:38SPEAKER_02: I want to thank my colleague Joe Coney for his astute insights and clinical uh expertise, as well as his leadership on advocating for all of our patients, making sure that one, they're equally represented in our trials and that they have equal access to our pharmaceuticals as well as clinical care.
- 57:59SPEAKER_02: And a special thanks uh and shout out to Natasha Cowdle for helping in the planning of this activity and providing her patient perspectives.
- 58:08SPEAKER_02: By way of summary, I'd like to offer three SMART goals.
- 58:11SPEAKER_02: SMART stands for specific, achievable, time-limited, measurable, and relevant.
- 58:17SPEAKER_02: Within three months of completing this activity, implement at least one enhancement in screening or diagnostic workflow for AMD, diabetic retinopathy, or inherited retinal diseases, such as adjusting follow-up intervals or standardizing documentation of disease severity in alignment with guidelines, to incorporate a structured discussion of at least one social determinant of health, for example, transportation, caregiver support, financial barriers, health literacy, language, into treatment planning for patients with retinal disease, and to also document it in the medical record.
- 58:53SPEAKER_02: And then finally, to improve confidence in explaining to patients how blood retinal barrier dysfunction contributes to disease progression and how emerging therapies are designed to address specific pathophysiologic mechanisms.
- 59:08SPEAKER_02: So, for additional resources, please visit the CME Outfitters website.
- 59:16SPEAKER_02: You can also visit the CME Outfitters Virtual Education Hub.
- 59:22SPEAKER_02: To receive credit for today's activity, please complete the post test and evaluation and thank you for participating.
- 59:30SPEAKER_02: Both Joe and I and Natasha appreciate your patience and attention.